How to Get Rezdiffra (Resmetirom) in Arizona

What Rezdiffra Is and Why It Matters for Arizona Patients

Rezdiffra (resmetirom) is the first drug approved by the FDA specifically for metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH. The March 2024 accelerated approval covers adults with noncirrhotic MASH and moderate to advanced liver fibrosis, staged F1b through F3 on histology. Arizona has an estimated 1.2 million adults with fatty liver disease, and a meaningful subset of those carry fibrotic MASH that now has a pharmacologic treatment option [1].

Resmetirom works as a selective thyroid hormone receptor beta (THR-beta) agonist. It targets the liver without producing systemic thyroid effects seen with nonselective thyroid hormones. In the MAESTRO-NASH trial (N=966), the 100 mg dose achieved MASH resolution without worsening fibrosis in 29.9% of patients at 52 weeks, compared to 9.7% on placebo [2]. That trial also showed a fibrosis improvement endpoint: 25.9% of patients on 80 mg improved by at least one fibrosis stage versus 14.2% on placebo [2].

These are not cure rates. They represent the first time any drug has cleared a regulatory bar for this disease. For Arizona patients, the practical question is straightforward: how do you actually get it?

Prescriber Eligibility in Arizona

Any Arizona-licensed physician (MD or DO) can prescribe Rezdiffra. Nurse practitioners with full prescriptive authority under Arizona's A.R.S. § 32-1601 may also prescribe, as can physician assistants working under a supervising physician agreement. Arizona is a full-practice-authority state for NPs, meaning no collaborative agreement with a physician is required for prescription [3].

Hepatologists and gastroenterologists are the most common prescribers given the diagnostic requirements, but endocrinologists and primary care physicians with experience in MASH management can also initiate therapy. The AASLD practice guidance on MASLD (2023) recommends that prescribing clinicians confirm fibrosis staging before starting therapy, which in practice means the prescriber needs familiarity with FibroScan interpretation or liver biopsy pathology [4].

A prescriber does not need to be physically located in Arizona if the consultation occurs via a properly established telehealth relationship under Arizona Revised Statutes Title 36, Chapter 36.

Telehealth Prescribing: How It Works in Arizona

Arizona permits telehealth prescribing of Rezdiffra. The state's telehealth laws, codified under A.R.S. § 36-3601, allow a provider-patient relationship to be established entirely through synchronous audio-video contact. No in-person visit is required before an initial prescription.

The typical telehealth workflow looks like this. A patient completes an intake form documenting their MASH diagnosis, fibrosis stage, current medications, and relevant lab history. The prescriber reviews existing imaging or pathology, orders any missing labs, and conducts a video consultation. If the patient meets criteria, the prescriber sends an electronic prescription to a specialty pharmacy. Most telehealth platforms complete this process in 5 to 10 business days from intake to prescription transmission.

Arizona does require that the prescribing provider hold an active Arizona medical license or be registered through the Interstate Medical Licensure Compact, which Arizona joined in 2017 [5]. Out-of-state telehealth providers without Arizona licensure cannot legally prescribe to Arizona residents.

One practical note: telehealth visits generate the same clinical documentation needed for prior authorization. Patients should request that their telehealth provider include FibroScan or biopsy results, ALT/AST values, and BMI in the visit summary, as insurers will ask for these during the PA process.

Required Labs and Diagnostics Before Starting Rezdiffra

The FDA label and clinical practice both require specific baseline assessments before initiating resmetirom. These are not optional screening tests. They determine eligibility and establish a monitoring baseline.

Liver fibrosis staging is the gatekeeper. The approved indication requires fibrosis stage F1b to F3. Staging can come from a liver biopsy (the gold standard used in MAESTRO-NASH) or from a validated noninvasive test. FibroScan (vibration-controlled transient elastography) with a liver stiffness measurement between 8.0 kPa and 13.9 kPa generally corresponds to significant fibrosis [6]. The Baveno VII consensus supports using liver stiffness measurement as a first-line fibrosis assessment [7].

Liver function tests (ALT, AST, bilirubin, albumin, INR) establish baseline hepatic function. In MAESTRO-NASH, resmetirom reduced ALT by a mean of 22% at 52 weeks in the 100 mg group [2]. Monitoring ALT at weeks 4, 8, and 12 after initiation is standard practice.

Thyroid function (TSH, free T4) must be checked because resmetirom is a THR-beta agonist. While it is liver-selective, the FDA label recommends ruling out uncontrolled thyroid disease before starting treatment [1].

Lipid panel is clinically valuable because resmetirom lowers LDL cholesterol. In MAESTRO-NASH, the 100 mg dose reduced LDL-C by approximately 14% at 52 weeks [2]. Patients already on statins may see additive lipid-lowering effects.

FIB-4 index (calculated from age, ALT, AST, and platelet count) can serve as an initial screening tool. A FIB-4 score above 1.3 warrants further evaluation with FibroScan or biopsy per AASLD guidance [4]. This test costs nothing beyond the standard blood draw.

Most Arizona commercial labs (Sonora Quest, LabCorp, Quest Diagnostics) can process all required bloodwork. FibroScan availability is more limited but is offered at most hepatology practices in Phoenix, Tucson, Scottsdale, and Flagstaff, and several mobile FibroScan services now cover rural Arizona counties.

Pharmacy Access and 503A Compounding in Arizona

Rezdiffra is distributed through specialty pharmacies. It is not stocked at standard retail pharmacies like CVS or Walgreens. The primary specialty pharmacy channel is coordinated through Madrigal Pharmaceuticals' distribution network.

Arizona-licensed 503A compounding pharmacies may also compound resmetirom. Under federal law (FDCA Section 503A), a 503A pharmacy compounds medications based on individual patient prescriptions. Arizona Board of Pharmacy regulations permit 503A pharmacies to dispense compounded prescriptions to patients within the state.

The distinction matters for cost. Brand-name Rezdiffra carries a list price of approximately $47,400 per year. A 503A compounded version, when available, may cost substantially less, though pricing varies by pharmacy. Patients should confirm with their prescriber whether a compounded formulation is appropriate for their situation and whether their insurer will cover it.

Specialty pharmacy fulfillment typically takes 3 to 7 business days after prior authorization approval. Patients in rural Arizona may experience slightly longer shipping times, but most specialty pharmacies offer direct-to-patient delivery via overnight or two-day carriers.

The Arizona State Board of Pharmacy maintains a searchable license verification tool where patients can confirm that a pharmacy holds a valid 503A permit.

Insurance, Prior Authorization, and Arizona Medicaid

Arizona Medicaid (AHCCCS) does not cover Rezdiffra as of May 2026. This leaves commercial insurance, Medicare Part D, and cash pay as the primary pathways.

Most commercial insurers that cover Rezdiffra require prior authorization. The PA process involves the prescriber submitting clinical documentation that demonstrates the patient meets the labeled indication. Required documents typically include:

• Confirmed MASH diagnosis (biopsy report or validated noninvasive markers)
• Fibrosis stage F1b to F3 (FibroScan report, FIB-4 calculation, or pathology)
• Baseline liver function tests
• Documentation that lifestyle interventions (diet, exercise) have been attempted
• Current medication list showing no contraindicated drug interactions
• BMI and metabolic comorbidity documentation

PA turnaround varies by insurer. Most Arizona commercial plans respond within 5 to 15 business days. If denied, patients have the right to appeal. The first-level appeal success rate for specialty hepatology drugs in Arizona commercial plans runs between 40% and 60%, based on industry data from the AMCP [8].

For Medicare Part D, coverage decisions depend on the specific plan formulary. Resmetirom received accelerated approval, and some Part D plans place accelerated-approval drugs on higher tiers or require step therapy. Patients should check their plan's formulary or call the number on their Medicare card.

Madrigal Pharmaceuticals offers the Rezdiffra Access Program, which includes copay assistance for commercially insured patients and a patient assistance program for uninsured or underinsured individuals. Eligible patients may pay as little as $0 per month out of pocket through the copay card, subject to annual caps.

Dosing, Administration, and Monitoring After Initiation

Rezdiffra is prescribed as an oral tablet taken once daily with food. The dose is weight-based:

• Patients weighing <100 kg: 80 mg once daily
• Patients weighing ≥100 kg: 100 mg once daily

The tablet should be swallowed whole. The prescribing information notes that resmetirom should be taken at least 4 hours apart from bile acid sequestrants, which can reduce absorption [1].

Monitoring after initiation follows a structured schedule. Liver function tests at weeks 4, 8, and 12 are standard. If ALT rises above 5 times the upper limit of normal, the FDA label recommends discontinuation [1]. Lipid panels at 12 weeks help quantify the LDL-lowering effect and guide statin co-management.

The AASLD recommends reassessing fibrosis status 12 to 24 months after starting pharmacotherapy for MASH [4]. This typically means a repeat FibroScan or, in select cases, a repeat liver biopsy to evaluate treatment response. A decrease in liver stiffness of ≥20% is generally considered clinically meaningful [7].

Dr. Zobair Younossi, chairman of the Global NASH Council, stated in a 2024 commentary: "For the first time, we have a drug that addresses the hepatic inflammation and fibrosis driving disease progression in MASH. The monitoring protocols are straightforward, and most can be managed in a primary care or telehealth setting" [9].

Patients should also report any new symptoms of diarrhea or nausea, which were the most common adverse events in MAESTRO-NASH (occurring in approximately 27% and 22% of patients on the 100 mg dose, respectively) [2]. Most GI side effects were mild to moderate and resolved within the first 12 weeks of treatment.

Timeline: From First Contact to First Dose in Arizona

A realistic timeline for an Arizona patient starting from no existing MASH workup:

Week 1 to 2: Initial consultation (in-person or telehealth), blood draws for liver panel, FIB-4, thyroid function, lipid panel. FibroScan scheduling if not done previously.

Week 2 to 4: FibroScan completed, results reviewed. If fibrosis stage confirms F1b to F3, prescriber initiates Rezdiffra prescription and submits prior authorization.

Week 4 to 6: Prior authorization determination. If approved, specialty pharmacy processes and ships medication.

Week 6 to 8: Patient receives medication. Follow-up labs scheduled at 4 weeks post-initiation.

Patients with an existing MASH diagnosis, recent FibroScan, and current labs can compress this timeline to 2 to 4 weeks. Telehealth pathways tend to be faster at the consultation stage but face the same PA timelines as in-person visits.

For patients transferring a Rezdiffra prescription from another state, the Arizona-licensed prescriber must issue a new prescription. Controlled substance transfer rules do not apply (resmetirom is not a controlled substance), but most specialty pharmacies require a new prescription from an Arizona-licensed provider rather than a simple transfer.

Rural Arizona Access Considerations

Arizona's geography creates access challenges. Maricopa and Pima counties have multiple hepatology practices with FibroScan capability. Patients in Coconino, Yavapai, Mohave, and Apache counties face longer drives for in-person hepatology visits.

Telehealth addresses the prescriber gap directly. The diagnostic gap, specifically FibroScan access, is harder to bridge remotely. Several solutions exist: Banner Health and HonorHealth operate mobile liver screening programs that periodically visit rural Arizona communities. The CDC's National Diabetes Prevention Program framework has also expanded metabolic screening in underserved areas, and some of these sites now include FibroScan [10].

For patients who cannot access FibroScan, the combination of FIB-4 index plus Enhanced Liver Fibrosis (ELF) test (a blood-based panel) provides a noninvasive alternative that can be processed at any commercial laboratory. The NICE guidelines endorse ELF as a second-line fibrosis assessment when elastography is unavailable [11].

Dr. Mary Rinella, writing in the 2023 AASLD guidance, noted: "Noninvasive tests have sufficient accuracy to identify patients with clinically significant fibrosis who would benefit from pharmacotherapy, reducing the need for liver biopsy in most cases" [4].